Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation
ConclusionsOur data reveal a dual mode of action of STF-31, serving either as a NAMPT or as a GLUT inhibitor, whereby the latter seems to be apparent only at higher STF-31 concentrations. The molecular basis of such a dual function and its appearance in compounds previously designated as NAMPT-specific inhibitors requires further investigation.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Bone Cancers | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Colon Cancer | Colorectal Cancer | Niacin | Oral Cancer | Osteosarcoma | Skin Cancer | Squamous Cell Carcinoma